Stocklytics Platform
Asset logo for symbol TMO
Thermo Fisher Scientific
TMO55
$568.20arrow_drop_down1.01%-$5.80
S&P500
Asset logo for symbol TMO
TMO55

$568.20

arrow_drop_down1.01%

Income Statement (TMO)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
EBIT-$2.16B$2.18B$1.72B$2.03B
EBITDA$2.01B$2.90B$2.97B$2.56B$2.87B
gross Profit$4.90B$4.32B$4.34B$4.21B$4.49B
NET Income$1.83B$1.63B$1.54B$1.32B$1.63B
total Revenue$11.39B$10.59B$10.54B$10.34B$10.88B

Balance Sheet (TMO)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
cash Equivalents-----
net Debt$27.26B$30.66B$28.32B$30.10B$26.84B
stockholders Equity$49.55B$48.99B$47.43B$45.51B$46.72B
total Assets$97.32B$100.36B$98.49B$97.09B$98.72B
total Debt$31.27B$35.31B$35.40B$35.60B$34.91B
total Liabilities$47.77B$51.26B$50.96B$51.47B$51.88B

Cash Flow (TMO)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow-$1.19B-$114.00M-$1.82B-$1.42B$1.85B
free Cash Flow$1.89B$1.65B$904.00M$3.31B$2.08B
investing Cash Flow-----$4.76B
operating Cash Flow$2.16B$1.96B$1.25B$3.72B$2.41B

Thermo Fisher Scientific (TMO) Financials

Thermo Fisher Scientific Inc (TMO) is a leading provider of scientific instruments, reagents, consumables, software, and services. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Thermo Fisher Scientific offers a broad range of products and solutions to meet the needs of its customers in various industries, including pharmaceuticals, biotechnology, academia, government, and healthcare.
The income statement provides an overview of Thermo Fisher Scientific's financial performance. It shows the company's revenue, expenses, and net income. In the most recent fiscal year, Thermo Fisher Scientific reported a total revenue of $25.5 billion. The company achieved a gross profit of $11.2 billion and a net income of $2.9 billion. These figures demonstrate Thermo Fisher Scientific's strong financial performance and its ability to generate profits.
EBIT, or earnings before interest and taxes, is an important measure of a company's profitability. Thermo Fisher Scientific's EBIT for the most recent fiscal year was $4.5 billion. This indicates that the company generated significant operating income before accounting for interest and taxes. EBITDA, or earnings before interest, taxes, depreciation, and amortization, is another measure of profitability. Thermo Fisher Scientific's EBITDA for the same period was $5.8 billion. Both EBIT and EBITDA reflect Thermo Fisher Scientific's strong financial position and its ability to generate profits from its operations.
Thermo Fisher Scientific's balance sheet provides a snapshot of the company's assets, liabilities, and stockholders' equity at a specific point in time. The company's total assets amounted to $60.2 billion, while its total liabilities were $27.3 billion. Thermo Fisher Scientific's stockholders' equity, which represents the residual interest in the assets after deducting liabilities, was $32.9 billion. The company's balance sheet reflects its strong financial position and its ability to meet its obligations.
Thermo Fisher Scientific's cash flow statement shows the cash inflows and outflows from its operating, investing, and financing activities. In the most recent fiscal year, the company generated $5 billion in operating cash flow, indicating its ability to generate cash from its core operations. Thermo Fisher Scientific also had positive financing cash flow of $3.1 billion, primarily driven by proceeds from the issuance of debt and equity. The company's investing cash flow was -$2.1 billion, mainly due to investments in property, plant, and equipment. Overall, Thermo Fisher Scientific's cash flow statement demonstrates its strong cash generation capabilities and its strategic investments to drive future growth.
In conclusion, Thermo Fisher Scientific Inc (TMO) has a strong financial position with significant revenue and profitability. The company's income statement highlights its ability to generate profits and its strong gross profit margin. Thermo Fisher Scientific's balance sheet reflects its strong assets and stockholders' equity, indicating its ability to meet its financial obligations. The company's cash flow statement demonstrates its strong cash generation capabilities and its strategic investments to drive future growth. Overall, Thermo Fisher Scientific is well-positioned in the market and continues to deliver value to its stakeholders.
add Thermo Fisher Scientific  to watchlist

Keep an eye on Thermo Fisher Scientific

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level